vorikonazol accordpharma 200mg prášek pro infuzní roztok
accord healthcare polska sp. z o.o., varšava array - 14426 vorikonazol - prášek pro infuzní roztok - 200mg - vorikonazol
vorikonazol viatris 200mg potahovaná tableta
viatris limited, dublin array - 14426 vorikonazol - potahovaná tableta - 200mg - vorikonazol
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastická činidla - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
modafen 200mg/30mg potahovaná tableta
stada arzneimittel ag, bad vilbel array - 1593 ibuprofen; 1227 pseudoefedrin-hydrochlorid - potahovaná tableta - 200mg/30mg - ibuprofen, kombinace
nurofen stopgrip 200mg/30mg potahovaná tableta
reckitt benckiser (czech republic), spol. s r.o., praha array - 1593 ibuprofen; 1227 pseudoefedrin-hydrochlorid - potahovaná tableta - 200mg/30mg - ibuprofen, kombinace
sulpirol 200mg tableta
hexal ag, holzkirchen array - 4417 sulpirid - tableta - 200mg - sulpirid
sulpirol 50mg tvrdá tobolka
hexal ag, holzkirchen array - 4417 sulpirid - tvrdá tobolka - 50mg - sulpirid
voriconazole accord 200mg prášek pro infuzní roztok
accord healthcare polska sp. z o.o., varšava array - 14426 vorikonazol - prášek pro infuzní roztok - 200mg - vorikonazol
cometriq
ipsen pharma - kabozantinib - onemocnění štítné žlázy - antineoplastická činidla - léčba dospělých pacientů s progresivním, neresekovatelným lokálně pokročilým nebo metastatickým karcinomem medulárního štítné žlázy.
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfom, mantle-cell - antineoplastická činidla - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).